# A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

> **NCT06506916** · PHASE3 · RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 90 (estimated)

## Conditions studied

- Moderate to Severe Plaque Psoriasis
- Psoriatic Arthritis

## Interventions

- **DRUG:** bimekizumab

## Key facts

- **NCT ID:** NCT06506916
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-29
- **Primary completion:** 2027-03-09
- **Final completion:** 2028-03-14
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06506916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06506916, "A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06506916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*